Back to Search Start Over

Prevalence and impact of comorbidities on disease prognosis among patients with COVID-19 in Bangladesh: A nationwide study amid the second wave

Authors :
Nadim Sharif
Abdullah Mohammad Shohael
Habibur Rahman
Raisah Jaheen
Nusaira Haque
Rubayet Rayhan Opu
Shuvra Kanti Dey
Suchana Islam
Ali Azam Talukder
Shamsun Nahar Ahmed
Muktasid Ud Daullah
Shahriar Khan
Umme Ayman
Mithun Kumar Sarkar
Faiza Islam
Fariha Bushra Khan
Nabila Haque
Mir Mubin
Source :
Diabetes & Metabolic Syndrome
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Background Socio-demographics and comorbidities are involved in determining the severity and fatality in patients with COVID-19 suggested by studies in various countries, but study in Bangladesh is insufficient. Aims We designed the study to evaluate the association of sociodemographic and comorbidities with the prognosis of adverse health outcomes in patients with COVID-19 in Bangladesh. Methods A multivariate retrospective cohort study was conducted on data from 966 RT-PCR positive patients from eight divisions during December 13, 2020, to February 13, 2021. Variables included sociodemographic, comorbidities, symptoms, Charlson comorbidity index (CCI) and access to health facilities. Major outcome was fatality. Secondary outcomes included hospitalization, duration of hospital stay, requirement of mechanical ventilation and severity. Results Male (65.8%, 636 of 966) was predominant and mean age was 39.8 ± 12.6 years. Fever (79%), dry cough (55%), and loss of test/smell (51%) were frequent and 74% patients had >3 symptoms. Fatality was recorded in 10.5% patients. Comorbidities were found in 44% patients. Hypertension (21.5%) diabetes (14.6%), and cardiovascular diseases (11.3%) were most prevalent. Age >60 years (OR: 4.83, 95% CI: 2.45–6.49), and CCI >3 (OR: 5.48, 95% CI: 3.95–7.24) were predictors of hospitalizations. CCI >4 (aOR: 3.41, 95% CI: 2.57–6.09) was predictor of severity. Age >60 years (aOR: 3.77, 95% CI: 1.07–6.34), >3 symptoms (aOR: 2.14, 95% CI: 0.97–4.91) and CCI >3 vs. CCI 3 symptoms, increasing comorbidities, higher CCI were associated with increased hospitalization, severity and fatality in patients with COVID-19.

Details

ISSN :
18714021
Volume :
15
Database :
OpenAIRE
Journal :
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Accession number :
edsair.doi.dedup.....e1ccd2ad7a02c79894e9afb7102086db
Full Text :
https://doi.org/10.1016/j.dsx.2021.05.021